Printer Friendly

CYGNUS ADDRESSES ANALYSTS, DISCUSSES COMPANY PROGRESS

 CYGNUS ADDRESSES ANALYSTS, DISCUSSES COMPANY PROGRESS
 SAN FRANCISCO, Jan. 7 /PRNewswire/ -- The company's focus on transdermal drug delivery has resulted in putting 13 products into development in less than six years, according to Gary Cleary, Ph.D., 48, founder and chairman of Cygnus Therapeutic Systems (NASDAQ: CYGN). Cygnus' products are in the therapeutic areas of smoking cessation, hormone replacement, pain management, cardiovascular disease, and central nervous system disorders.
 The transdermal nicotine patch designed by Cygnus to help smokers quit is expected to be launched in the first half of the year under the trade name Nicotrol(TM) 16 hr. The manufacturing facility is completed and a pre-approval plant inspection by the FDA is scheduled, Cleary announced here today at the annual Hambrecht & Quist Life Sciences Conference. Cygnus custom-engineered the nicotine patch under contract to Kabi Pharmacia, the developer of Nicorette(TM) chewing gum. It will be marketed by Warner-Lambert Co. in the United States.
 Cygnus anticipates a New Drug Application will be filed in the first half of 1992 for its fentanyl transdermal patch for the management of severe pain. Anaquest, a leading supplier of anesthetic drugs and gases to the hospital operating room, will market the patch in the United States and Canada.
 Cleary said Phase III clinical trials will begin first quarter with its estrogen patch for symptoms of menopause. The estradiol patch is licensed to Sanofi and will be marketed in the United States by Warner-Lambert.
 The company has grown to 128 employees, and incurred significant R&D expenses in 1991, primarily in process development and start up manufacturing costs, according to Shirley Clayton, chief financial officer. Cygnus anticipates its year-end loss will be generally in the range of analysts' projections. The company has completed its 20,000 square foot manufacturing facility at a cost of approximately $6 million, and will end the year with approximately $22 million in cash, Clayton said.
 In other related matters, Cleary, chairman and chief technical officer, who has principal responsibility for the nicotine patch manufacturing ramp up, will be a member of a new operating committee that also includes David de Weese, president and chief executive officer, and Clayton.
 Headquartered in Redwood City, Calif., Cygnus Therapeutic Systems is the only company concentrating exclusively on the design, development and manufacture of transdermal drug delivery systems.
 -0- 1/7/92
 /CONTACT: Shirley Clayton of Cygnus, 415-369-4300; or Susan Atkins of Susan Atkins PR, 415-921-5929, for Cygnus/ CO: Cygnus Therapeutic Systems ST: California IN: MTC SU:


DG -- SF006 -- 7521 01/07/92 18:02 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 7, 1992
Words:421
Previous Article:PRESIDENT OF ITALY COMING TO CHICAGO TO RECEIVE HONORARY DEGREE FROM LOYOLA UNIVERSITY CHICAGO
Next Article:AMERICA FIRST ANNOUNCES PROFITABLE SALE OF MORTGAGES
Topics:


Related Articles
USE OF ELAN'S PATCH DOUBLES QUIT RATE AT ONE YEAR
CYGNUS NICOTINE PATCH APPROVED IN CANADA
CYGNUS AND YAMANOUCHI SIGN AGREEMENT FOR PAINLESS, CONTINUOUS GLUCOSE MONITOR
Cygnus Introduces a Fax-on-Demand Service to Expedite Information to the Financial Community
Pharmacia & Upjohn to Purchase U.S. Manufacturing Rights for NICOTROL(R) From Cygnus
Cygnus Seeks Alliance for GlucoWatch Monitor; Clinical Studies to Begin In Japan
NDA Submitted for 7-day Estrogen Patch Developed by Cygnus; American Home Products has World-Wide Marketing Rights.
Cygnus' GlucoWatch(R) Monitor Approved for Sale in Europe.
Cygnus Completes $10 Million Asset Sale to Animas.
Cygnus to Appeal Nasdaq National Market Delisting Notification.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters